Axonics, Inc. (AXNX)

67,32 -0,06 (-0,09%) Börsenschluss: 04:00PM EDT

Axonics, Inc.

26 Technology Drive
Irvine, CA 92618
United States
949 396 6322
https://www.axonics.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 797

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Raymond W. Cohen	CEO & Director	1,75M	N/A	1959
Ms. Kari Keese	Chief Financial Officer	1,64M	46,74k	1985
Mr. Rinda K. Sama	Chief Operating Officer	888,2k	N/A	1979
Dr. John Woock Ph.D.	Executive VP, Chief Marketing & Strategy Officer	888,2k	1,51M	1983
Mr. Alfred J. Ford Jr.	Chief Commercial Officer	909,52k	1,9M	1971
Mr. Guangqiang Jiang Ph.D.	Chief Technology Officer	N/A	N/A	1974
Mr. Neil Bhalodkar	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Aaron Pettit	General Counsel & Chief Compliance Officer	N/A	N/A	N/A
Mr. Michael V. Williamson Esq., J.D.	Senior VP, General & IP Counsel	N/A	N/A	1972
Dr. Karen L. Noblett M.A.S., M.D.	Chief Medical Officer	651,4k	897,47k	1963

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Corporate Governance

Axonics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 10, Vorstand: 3, Shareholderrechte: 4, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.